A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 23, 2023

Primary Completion Date

February 21, 2024

Study Completion Date

February 21, 2024

Conditions
Hemophilia
Interventions
DEVICE

Virtual-reality (VR) Based Solution

VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).

Trial Locations (6)

4093

Hôpital Hôtel-Dieu, Nantes

7200

Hôpital de Hautepierre - Pôle MIRMED, Strasbourg

31059

CHU Purpan, Toulouse

33076

CHU Pellegrin, Bordeaux

69003

CHU Estaing, Clermont-Ferrand

69677

Centre de Reference Hemophilie Unite D'Hemostase Clinique, Bron

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY